What is Hyperphosphatemia?

Hyperphosphatemia is a condition that is characterized by an increased level of phosphate in the blood. It is asymptomatic effect/condition of another major underlying cause. The normal range for phosphorous is 2.5-4.5 mg/dL. Normal values may vary from laboratory to laboratory. It can result from the enhanced concentration of phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. However, as mentioned above elevated phosphate levels are less commonly associated with morbidity in patients with this disorder than with an underlying disease.

Hyperphosphatemia is most often caused by kidney failure. Healthy kidneys may regulate mineral levels in the blood, but kidneys that are not functioning properly cannot always do so. However, there are other conditions related to elevated phosphate levels in the blood, including the following: Uncontrolled Diabetes, Ketoacidosis in diabetics, hyperparathyroidism, and hypocalcemia.

Taking a phosphate supplement can also lead to Hyperphosphatemia. Most people will get more than enough phosphorus from their diet, and the body is usually good at regulating levels. It is advised not to take more than 250 milligrams (mg) of phosphorus supplements per day. Processed foods often have phosphorus added to preserve them, and a high-protein diet may also contain more phosphorus than someone needs.

Also, Read- Hyperphosphatemia Market

Patients with Hyperphosphatemia are generally not presented with any kind of symptoms initially, later on, with the progression of the condition, common symptoms such as fatigue, loss of appetite, dry skin and itching, inability to urinate, body pain, and changes in skin color are observed.

The diagnosis for Hyperphosphatemia incorporates having a brief look into the patient’s medical history, discussion of symptoms, physical examination, urine analysis, and measuring the levels of phosphate in the plasma. To provide aid from the said condition, several treatment and therapy modalities such as approved drugs, dietary modifications, changes in lifestyle, phosphate binders, etc. are available in the market.

The increase in market size is a direct consequence of an increase in prevalent cases of chronic kidney disease and patients progressing towards end-stage renal disease. Emerging therapies that are targeting the issues of safety concerns and pill burden of currently approved phosphate binders are also expected to influence the market size in the 7MM during the forecast period.

Hyperphosphatemia is common in the late stages of chronic kidney disease and is often associated with elevated parathormone levels, abnormal bone mineralization, extra-osseous calcification, and increased risk of cardiovascular events and death. Several classes of oral phosphate binders are available to help control plasma phosphorus levels. Although effective at lowering serum phosphorus, they all have safety, tolerability, and compliance issues that need to be considered when selecting which one to use.

Excess phosphorus levels in ESRD have been linked to a rise in the risk of cardiovascular disease, as well as rises in serum Fibroblast growth factor 23 (FGF-23), a significant serum endocrine hormone that controls phosphorus metabolism, and elevated parathyroid hormone, also known as secondary hyperparathyroidism.